Aiforia Technologies Plc, Company Release, Managers’ Transactions, March 16, 2026 at 17:00 EET

Aiforia Technologies Plc – Managers’ Transactions – Panu Kauppila

Aiforia Technologies Plc has received a notification from Panu Kauppila, Aiforia Technologies Plc's member of the management team, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.

____________________________________________

Aiforia Technologies Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Panu Ilmari Kauppila

Position: Other senior manager

Issuer: Aiforia Technologies Oyj

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 147272/8/4

____________________________________________

Transaction date: 2026-03-13

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 5000 Unit price: 1.85 EUR

Aggregated transactions (1):

Volume: 5000 Volume weighted average price: 1.85 EUR

Further inquiries
Antti Ojala, CFO, Aiforia Technologies Plc,
tel. +358 40 7202448
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Find out more at www.aiforia.com